Pfizer Inc. has failed again in enforcing its intellectual property rights in India. The giant pharmaceutical's patent on its rheumatoid arthritis drug, Tofacitinib, was rejected in the country.
Breaking News
Subscribe to VCpost newsletter
Most Popular
- IRS Scrambles to Address Huge Gap in Audit Rates Between Black, Other Taxpayers
- Joe Biden Administration Sanctions Colombian Maritime Companies Preying on Vulnerable Migrants Seeking to Enter US
- Hims & Hers CEO Responds to Backlash After Facing Stock Plunge Over Comments Praising Anti-Israel Protesters
- Americans Brace for Another Round of Higher Housing Costs, NY Fed Survey Shows
- Social Security and Medicare Get Boost From Stronger US Economy, But Funds Expected to Run Short in 2035
- Xi Jinping Urges France to Resist 'New Cold War' Amid EU's Shift Towards US Alliance
- EU is Set to Intensify Sanctions Against Russia Amid Report Kremlin Plots Sabotage Attack
- Over 1,000 Denver International Airport Flights Delayed Over Wind Gusts